We’re excited to announce that the Sentinel® Cerebral Embolic Protection System has received @CMSGov NTAP designation following our acquisition of Claret Medical. https://t.co/tN2HBfFrka
We would like to congratulate our client @claret_medical on the positive reimbursement news with NTAP designation and the close of its acquisition from @bostonsci! This reinforces the importance of using cerebral embolic protection devices during #TAVR. #ProtectedTAVR
Great feature on @bostonsci's acquisition of @claret_medical, by @LizMedtech. "It was really an easy consideration for the organization to look at cerebral embolic protection, and within this context, Claret is [the] undisputed leader" https://t.co/3vCH3stWqZ #ProtectedTAVR#TAVR
We’ve announced an agreement to acquire @claret_medical and look forward to adding their Sentinel® Cerebral Embolic Protection System to our interventional cardiology portfolio. https://t.co/RNiC9XOUen $BSX
Exciting news for our client @claret_medical! Congrats on the $270M acquisition from @bostonsci, validating the value of #ProtectedTAVR with the Sentinel System as an extra layer of protection against #stroke for patients undergoing #TAVR. https://t.co/5De9K90oYm
Congratulations @claret_medical! There's a lot of value in #protectedtavr for #stroke prevention - clearly @bostonsci knows this! https://t.co/eSik8biasb
Boston Scientific to buy @claret_medical - the company behind Sentinel, a EU & US approved cerebral protection device. Boston says it sees "potential" for device to be used in procedures other than TAVI. https://t.co/zgq7TKujBM